In conclusion, selected SMO antagonist-resistant metastatic basal cell carcinomas may respond to nivolumab based on underlying molecular genetic mechanisms that include <i>PD-L1</i> amplification and high tumour mutational burden. This evidence concerns the gene SMO and basal cell carcinoma.